摘要
目的采用高效液相色谱(HPLC)法同时测定甲苯磺酸妥舒沙星中4种遗传毒性杂质(2,4-二氟苯胺、2,6-二氟苯胺、对甲苯磺酸甲酯和对甲苯磺酸乙酯)的含量。方法采用CAPCELL PAK C18柱(4.6 mm×250 mm,5μm)色谱柱;流动相为乙腈-水,梯度洗脱;柱温为35℃;流速为0.8 mL·min^(-1);检测波长为225 nm。结果2,4-二氟苯胺、2,6-二氟苯胺、对甲苯磺酸甲酯和对甲苯磺酸乙酯质量浓度分别在0.0404~0.6064μg·mL^(-1)(r=0.9997)、0.0282~0.6055μg·mL^(-1)(r=0.9998)、0.0403~0.6045μg·mL^(-1)(r=0.9997)、0.0401~0.6019μg·mL^(-1)(r=0.9999)与峰面积呈良好的线性关系,平均加样回收率在95.9%~101.3%,RSD在0.40%~7.3%。结论该方法专属性强,重复性好,准确度高,可为甲苯磺酸妥舒沙星的质量控制及标准研究提供参考。
Objective To simultaneously determine 4 genotoxic impurities(2,4-difluoroaniline,2,6-difluoroaniline,methyl p-toluenesulfonate and ethyl p-toluenesulfonate)in tosufloxacin tosylate hydrate by HPLC.Methods The determination was performed on a CAPCELL PAK C18(4.6 mm×250 mm,5μm)column,and the mobile phase was acetonitrile-water with gradient elution at 0.8 mL·min^(-1).The column temperature was 35℃.The detection wavelength was 225 nm.Results The concentration of 2,4-difluoroaniline,2,6-difluoroaniline,methyl p-toluenesulfonate and ethyl p-toluenesulfonate was 0.0404~0.6064μg·mL^(-1)(r=0.9997),0.0282~0.6055μg·mL^(-1)(r=0.9998),0.0403~0.6045μg·mL^(-1)(r=0.9997),and 0.0401~0.6019μg·mL^(-1)(r=0.9999),with a good linearity in the peak area.The average recovery was at 95.9%~101.3%with RSD at 0.40%~7.3%,respectively.Conclusion The method is validated,with strong specificity,good repeatability and high accuracy,which can provide reference for the quality control and standard research of tosufloxacin tosylate hydrate.
作者
陈鸿玉
程雪清
廖漾
周碧红
刘栋华
刘雁鸣
李昌亮
CHEN Hong-yu;CHENG Xue-qing;LIAO Yang;ZHOU Bi-hong;LIU Dong-hua;LIU Yan-ming;LI Chang-liang(Hunan Institute for Drug Control,Hunan Engineering&Technology Research Center for Pharmaceutical Quality Evaluation,Key Laboratory of Pharmaceutical Excipients Engineering Technology of State Drug Administration,Changsha 410001;Hinye Pharmaceutical Co.,Ltd.,Hunan Osteoarthritis Drug Engineering Technology Research Center,Hunan Engineering&Technology Research Center for Pharmaceutical Quality Evaluation,Changsha 410331;Hinye Pharmaceutical Co.,Ltd.,Changsha 410331)
出处
《中南药学》
CAS
2022年第12期2901-2905,共5页
Central South Pharmacy
基金
湖南科药联合基金项目(No.2021JJ80003)。